美国补充支付批准技术的评估。
Evaluation of technologies approved for supplemental payments in the United States.
机构信息
Department of Medicine, University of California, San Francisco, 505 Parnassus Ave, San Francisco, CA 94143, USA.
San Francisco VA Medical Center, Section of Cardiology, San Francisco, CA 94121, USA.
出版信息
BMJ. 2019 Jun 17;365:l2190. doi: 10.1136/bmj.l2190.
Abstract
Supplemental payment programmes can increase access to new technologies, but find that some payments are made without clear evidence of safety and effectiveness
摘要
补充支付计划可以增加获得新技术的机会，但我们发现一些支付是在没有明确的安全性和有效性证据的情况下进行的。
相似文献
1
Evaluation of technologies approved for supplemental payments in the United States.美国补充支付批准技术的评估。
BMJ. 2019 Jun 17;365:l2190. doi: 10.1136/bmj.l2190.
2
The recent decision by the Centers for Medicare and Medicaid Services to revalue evaluation and management codes and its negative financial impact on cardiothoracic surgery.医疗保险和医疗补助服务中心最近重新评估评估与管理代码的决定及其对心胸外科手术的负面财务影响。
J Thorac Cardiovasc Surg. 2022 Mar;163(3):1108-1113. doi: 10.1016/j.jtcvs.2021.02.105. Epub 2021 Apr 16.
3
Vascular specialist response to medicare evidence development coverage advisory committee (MEDCAC) panel on peripheral artery disease of the lower extremities.血管专家对医疗保险证据开发覆盖咨询委员会（MEDCAC）关于下肢外周动脉疾病小组的回应。
Catheter Cardiovasc Interv. 2016 Jun;87(7):1181-6. doi: 10.1002/ccd.26512. Epub 2016 Apr 10.
4
Impact of a National Bariatric Surgery Center of Excellence Program on Medicare Expenditures.国家卓越减重手术中心项目对医疗保险支出的影响。
J Gastrointest Surg. 2016 Apr;20(4):708-14. doi: 10.1007/s11605-015-3027-5. Epub 2015 Nov 18.
5
Longitudinal patterns of Medicaid and Medicare coverage among disability cash benefit awardees.残疾现金福利受助人中医疗补助计划和医疗保险覆盖的纵向模式。
Soc Secur Bull. 2012;72(3):19-35.
6
Introduction, Cancellation, and Future Promise of Medicare Cardiac Episode Payment Models.医疗保险心脏疾病发作支付模式的介绍、取消及未来前景
Circ Cardiovasc Qual Outcomes. 2018 Jan;11(1). doi: 10.1161/CIRCOUTCOMES.117.004345.
7
Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.医疗保险处方药计划在 FDA 批准后对新治疗药物的覆盖范围。
J Manag Care Spec Pharm. 2018 Dec;24(12):1230-1238. doi: 10.18553/jmcp.2018.24.12.1230.
8
The Centers for Medicare & Medicaid Services' Overhaul of Office-Visit Payments-What's the Bottom Line for Otolaryngology?医疗保险和医疗补助服务中心对门诊支付的改革——耳鼻喉科的最终结果是什么？
JAMA Otolaryngol Head Neck Surg. 2019 Apr 1;145(4):303-304. doi: 10.1001/jamaoto.2018.4154.
9
The Role Of Social, Cognitive, And Functional Risk Factors In Medicare Spending For Dual And Nondual Enrollees.社会、认知和功能风险因素在双重和非双重参保者的医疗保险支出中的作用。
Health Aff (Millwood). 2019 Apr;38(4):569-576. doi: 10.1377/hlthaff.2018.05032.
10
Medicare and cost-effectiveness analysis.医疗保险与成本效益分析。
N Engl J Med. 2005 Oct 6;353(14):1516-22. doi: 10.1056/NEJMsb050564.
引用本文的文献
1
Medicine, emotience, and reason.医学、情感和理性。
Philos Ethics Humanit Med. 2024 Apr 10;19(1):5. doi: 10.1186/s13010-024-00154-y.
2
Insurance payment for artificial intelligence technology: Methods used by a stroke artificial intelligence system and strategies to qualify for the new technology add-on payment.人工智能技术的保险支付：中风人工智能系统使用的方法和符合新技术附加支付的策略。
Neuroradiol J. 2022 Jun;35(3):284-289. doi: 10.1177/19714009211067408. Epub 2022 Jan 6.
3
Brain-Computer Interfaces in Neurorecovery and Neurorehabilitation.脑机接口在神经康复和神经修复中的应用。
Semin Neurol. 2021 Apr;41(2):206-216. doi: 10.1055/s-0041-1725137. Epub 2021 Mar 19.
4
The Changing Characteristics of Technologies Covered by Medicare's New Technology Add-on Payment Program.医疗保险新增支付项目涵盖的技术的变化特征。
JAMA Netw Open. 2020 Aug 3;3(8):e2012569. doi: 10.1001/jamanetworkopen.2020.12569.
本文引用的文献
1
Prices For Cardiac Implant Devices May Be Up To Six Times Higher In The US Than In Some European Countries.美国心脏植入设备的价格可能比一些欧洲国家高出六倍之多。
Health Aff (Millwood). 2018 Oct;37(10):1570-1577. doi: 10.1377/hlthaff.2017.1367.
2
NICE, the NHS, and Cancer Drugs.英国国家卫生与临床优化研究所、英国国家医疗服务体系与癌症药物
JAMA. 2018 Feb 27;319(8):767-768. doi: 10.1001/jama.2017.20552.
3
Physicians' Knowledge About FDA Approval Standards and Perceptions of the "Breakthrough Therapy" Designation.医生对美国食品药品监督管理局（FDA）批准标准的了解以及对“突破性疗法”认定的看法。
JAMA. 2016 Apr 12;315(14):1516-8. doi: 10.1001/jama.2015.16984.
4
Analysis of FDA-Approved Orthopaedic Devices and Their Recalls.美国食品药品监督管理局（FDA）批准的骨科器械及其召回情况分析。
J Bone Joint Surg Am. 2016 Mar 16;98(6):517-24. doi: 10.2106/JBJS.15.00286.
5
Adoption and de-adoption of drotrecogin alfa for severe sepsis in the United States.美国严重脓毒症患者对重组人活化蛋白C（drotrecogin alfa）的使用与停用情况。
J Crit Care. 2016 Apr;32:114-9. doi: 10.1016/j.jcrc.2015.12.007. Epub 2015 Dec 11.
6
A Randomized Trial Testing US Food and Drug Administration "Breakthrough" Language.一项测试美国食品药品监督管理局“突破性”措辞的随机试验。
JAMA Intern Med. 2015 Nov;175(11):1856-8. doi: 10.1001/jamainternmed.2015.5355.
7
Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure.意大利目前基于绩效的方案真的有效吗？“成功费”：一种控制药品支出成本的新措施。
Value Health. 2015 Mar;18(2):352. doi: 10.1016/j.jval.2014.12.003. Epub 2015 Jan 22.
8
US hospital payment adjustments for innovative technology lag behind those in Germany, France, and Japan.美国医院对创新技术的支付调整落后于德国、法国和日本。
Health Aff (Millwood). 2015 Feb;34(2):261-70. doi: 10.1377/hlthaff.2014.1017.
9
Paclitaxel-eluting stents for the treatment of femoropopliteal arterial stenoses: focus on the Zilver PTX drug-eluting peripheral stent.用于治疗股腘动脉狭窄的紫杉醇洗脱支架：聚焦于Zilver PTX药物洗脱外周支架
Expert Rev Med Devices. 2015 Mar;12(2):157-62. doi: 10.1586/17434440.2015.985653. Epub 2014 Nov 24.
10
Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals.美国食品药品监督管理局（FDA）加快药品审批的时代，黑框警告和药品退市情况也有所增加。
Health Aff (Millwood). 2014 Aug;33(8):1453-9. doi: 10.1377/hlthaff.2014.0122.
Zotero 插件